Archives
-
Liver sEH–Nrf2 Control of Osteoclastogenesis
2026-08-22
A 2025 study identifies a liver–bone axis in which hepatic soluble epoxide hydrolase alters circulating epoxide metabolites and inflammatory signals, thereby suppressing Nrf2-ARE activity in bone and promoting osteoclast differentiation. Its integrated clinical, animal, cellular, and transcriptomic design provides a mechanistic framework for studying redox imbalance in osteoporosis and related enzyme inhibition studies.
-
Dual-Action p38α Inhibitors and Dephosphorylation
2026-08-22
A 2024 bioRxiv preprint shows that selected kinase inhibitors can do more than occupy the p38α catalytic site: they can also accelerate activation-loop dephosphorylation by WIP1. Structural and biochemical evidence supports a mechanism in which inhibitor-stabilized loop conformations expose phospho-threonine, suggesting a route to more durable and target-selective kinase inhibition.
-
Gemcitabine Workflows for DNA Damage Research
2026-08-21
Gemcitabine provides a practical benchmark for connecting replication stress with checkpoint activation, cell-cycle arrest, and apoptosis. This workflow combines dose-ranging, orthogonal phenotyping, and transcriptomics-informed assay design for cancer research, including osteosarcoma models.
-
Linoleic Acid–PPARα–TF Signaling in pLELC
2026-08-20
This reference study integrates serum proteomics, untargeted metabolomics, functional testing, and a patient-derived xenograft model to investigate primary pulmonary lymphoepithelioma-like carcinoma. It proposes a linoleic acid–PPARα–tissue factor axis that reshapes immune-cell infiltration and promotes tumor progression, positioning tissue factor as a candidate therapeutic target while highlighting the context dependence of PPARα signaling.
-
Aprotinin Workflows for Protease-Controlled Assays
2026-08-20
Aprotinin enables reversible control of trypsin, plasmin, and kallikrein in blood, cell, and inflammation research workflows. This guide connects fibrinolysis inhibition and cardiovascular surgery blood management models with membrane-biophysics assay design, while emphasizing formulation controls and troubleshooting.
-
Pyridostatin TFA in G-Quadruplex Research
2026-08-19
Pyridostatin TFA provides a practical way to stabilize G-quadruplexes while connecting telomere biology research with emerging studies of nucleic-acid-regulated protein condensation. This workflow-focused guide covers dose design, assay controls, comparative applications, and troubleshooting for cancer and neurodegeneration-oriented experiments.
-
Streptozotocin: Designing Causal Diabetes Models
2026-08-19
Streptozotocin enables controlled experimental diabetes mellitus induction through selective pancreatic β-cell cytotoxicity. This guide moves beyond model generation to show how STZ can support rigorous causal studies of diabetic neuropathy, inflammation, and therapeutic response.
-
Methicillin Sodium Salt for MSSA Research
2026-08-18
Build reproducible MSSA susceptibility, cell-wall stress, and infection-model workflows with Methicillin sodium salt. This guide distinguishes actionable MSSA benchmarking from MRSA resistance analysis and provides practical setup, optimization, and troubleshooting strategies.
-
Ribonuclease R (RNase R) (20 U/μL) Guide
2026-08-18
Learn how Ribonuclease R (RNase R) (20 U/μL), SKU K3061, can strengthen circular RNA validation before interpreting cell proliferation, viability, or cytotoxicity phenotypes. This scenario-driven guide covers experimental controls, protocol calculations, data interpretation, and practical product-selection criteria.
-
TRIM21, ERK1/2, and Drug Resistance in Pituitary Adenomas
2026-08-17
The reference study identifies TRIM21 as a regulator of pituitary adenoma proliferation and dopamine-agonist resistance through K27-linked ubiquitination and phosphorylation of ERK1/2. Its combination of CRISPR screening, proteomics, interaction assays, animal studies, and NanoBiT drug screening positions TRIM21 as a mechanistically testable therapeutic target and highlights Quisinostat as a candidate for reducing resistance-associated signaling.
-
Neurotensin Workflows for GPCR Trafficking
2026-08-17
Turn Neurotensin receptor 1 activation into a structured workflow for receptor recycling, miR-133α modulation, and gastrointestinal cell studies. This guide combines peptide-handling discipline with interference-aware fluorescence analysis and practical troubleshooting.
-
SM-164: Bivalent Smac Mimetic Assay Guide
2026-08-16
SM-164 provides a practical way to connect rapid IAP degradation with TNFα-dependent apoptosis, caspase activation, and tumor-cell killing. This workflow guide shows how to use it as a mechanistic apoptosis probe, an orthogonal comparator for transcriptional inhibitors, and a reproducible tool for cancer research.
-
Protease and Phosphatase Inhibitor Cocktail Workflow
2026-08-15
Protect phosphorylation-dependent signaling data and protein integrity across cell, organoid, tissue, plant, yeast, and bacterial lysates. This EDTA-free 100X format is especially useful when metal chelation could interfere with downstream assays or when rapid, standardized sample stabilization is essential.
-
Biotin (Vitamin B7) for Motor Protein Assays
2026-08-14
Biotin (Vitamin B7) enables controlled avidin–streptavidin capture, blocking, and detection workflows for reconstituted motor-protein experiments. This guide connects A8010’s practical solution chemistry with the BicD–MAP7–kinesin findings, while clarifying when free biotin is appropriate and when an activated biotinylation reagent is required.
-
DAPI Nuclear Stain Solution Protocol
2026-08-14
DAPI (4',6-Diamidino-2-Phenylindole) Nuclear Stain Solution provides a pre-diluted fluorescent DNA binding dye for nuclear visualization and endpoint cell viability assessment. It is best suited to fixed or membrane-compromised samples analyzed by fluorescence microscopy or flow cytometry, not primary live-cell imaging.